Vericiguat - Moligand™, ≥98% , Soluble guanylate cyclase activator, CAS No.1350653-20-1, Soluble guanylate cyclase activator
En stock
SKU
V414461
Guanylate Cyclase Modulators
Information
Vericiguat Vericiguat (BAY1021189, Verquvo) is a potent, orally available and soluble guanylate cyclase (sGC) stimulator.
Targets
sGC
In vitro
The stimulation of sGC by Vericiguat is examined with a recombinant CHO cell line overexpressing rat sGC. Vericiguat stimulates the sGC reporter cell line concentration dependently with an EC50 of 1005 ± 145 nM. In the presence of the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) (30 and 100 nM), the EC50 value shifts to 39.0 ± 5.1 and 10.6 ± 1.7 nM, respectively. In the presence of ODQ, pretreatment of the sGC reporter cell line with 10 μM ODQ for 3 h results in a significantly reduced efficacy of Vericiguat, with an EC50 of 256 ± 40 nM being observed.
In vivo
Vericiguat can maintain heart and kidney function in a model of hypertension-induced end-organ damage with substantially reduced overall mortality.
Cell Research(from reference)
Cell lines：CHO cells
Concentrations：0.01 μM to 100 μM
Incubation Time：6 min
Plus d’information
| CAS | 1350653-20-1 |
|---|---|
| Synonymes | Vericiguat [USAN] | methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate | SB16806 | 1350653-20-1 | DS-2178 | VERICIGUAT [JAN] | WHO 9805 | D11051 | Vericiguat | AKOS025289795 | BCP18886 | Methyl |
| Spécifications et pureté | Moligand™, ≥98% |
| Conditions de stockage de stockage | Store at -20°C |
| Expédié en | Ice chest + Ice pads |
| Product Description | Information Vericiguat Vericiguat (BAY1021189, Verquvo) is a potent, orally available and soluble guanylate cyclase (sGC) stimulator. Targets sGC In vitro The stimulation of sGC by Vericiguat is examined with a recombinant CHO cell line overexpressing rat sGC. Vericiguat stimulates the sGC reporter cell line concentration dependently with an EC50 of 1005 ± 145 nM. In the presence of the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) (30 and 100 nM), the EC50 value shifts to 39.0 ± 5.1 and 10.6 ± 1.7 nM, respectively. In the presence of ODQ, pretreatment of the sGC reporter cell line with 10 μM ODQ for 3 h results in a significantly reduced efficacy of Vericiguat, with an EC50 of 256 ± 40 nM being observed. In vivo Vericiguat can maintain heart and kidney function in a model of hypertension-induced end-organ damage with substantially reduced overall mortality. Cell Research(from reference) Cell lines：CHO cells Concentrations：0.01 μM to 100 μM Incubation Time：6 min |
| Pubchem Sid | 504771336 |
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504771336 |
| Solubilité | Solubility (25°C) In vitro DMSO: 85 mg/mL (199.35 mM); Water: Insoluble; Ethanol: Insoluble; |
| PubChem CID | 54674461 |
Avis
Avis des clients
Remind me later